Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

BACKGROUND: Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. METHODS:...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Nephrol
Huvudupphovsmän: Hansrivijit, Panupong, Cheungpasitporn, Wisit, Thongprayoon, Charat, Ghahramani, Nasrollah
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2020
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160971/
https://ncbi.nlm.nih.gov/pubmed/32293308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-020-01797-7
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk